Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Axplora","sponsor":"Lysogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novasep and Lysogene Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Axplora","sponsor":"Sensorion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Axplora","sponsor":"Breckenridge Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teriflunomide \u2013 API and Licensing Agreements for Tablets Available","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Axplora","sponsor":"Paratek Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novasep And Paratek Enhance Collaboration to Manufacture Omadacycline (NUZYRA\u00ae), A Novel Tetracycline-Class Antibiotic for The Treatment of Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Axplora","sponsor":"McSAF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"McSAF and Novasep Announce Their Successful Collaboration To Produce A Next-generation Antibody-Drug Conjugate (ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Axplora

    Menu

    Axplora

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    INTERMEDIATES

    SERVICES

    Key Services KEY SERVICES

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Axplora

              Contact Supplier
              • Deals
              Virtual BoothAxplora- The partner of choice for complex APIs.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novasep And Paratek Enhance Collaboration to Manufacture Omadacycline (NUZYRA®), A Novel Tetracycline-Class Antibiotic for The Treatment of Bacterial Infections

              Details:

              Under the terms of the collaboration, Novasep and Paratek will manufacture NUZYRA® (omadacycline), an FDA-approved tetracycline-class, once-daily oral and intravenous antibiotic for the treatment of adults with CABP and acute bacterial skin and skin structure infections.

              Lead Product(s): Omadacycline

              Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Paratek Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 15, 2022

              Axplora CB

              Iran Expo

              Not Confirmed

              envelop Contact Supplier

              Axplora

              Contact Supplier
              • Deals
              Virtual BoothAxplora- The partner of choice for complex APIs.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              McSAF and Novasep Announce Their Successful Collaboration To Produce A Next-generation Antibody-Drug Conjugate (ADC)

              Details:

              Novasep has successfully optimized and scaled-up the process of Adcitmer® (monomethyl auristatin E-conjugated antibody), McSAF Inside® Oncology’s first-in-class proprietary ADC to treat neuroendocrine cancers.

              Lead Product(s): Monomethyl Auristatin E-Conjugated Antibody

              Therapeutic Area: Oncology Product Name: Adcitmer

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: McSAF

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 18, 2021

              Axplora CB

              Iran Expo

              Not Confirmed

              envelop Contact Supplier

              Axplora

              Contact Supplier
              • Development Update
              Virtual BoothAxplora- The partner of choice for complex APIs.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Teriflunomide – API and Licensing Agreements for Tablets Available

              Details:

              The received FDA approval will allow Breckenridge, to launch generic Teriflunomide in the US market from the beginning of 2023 onwards. Teriflunomide, a small molecule is a generic of Aubagio® available in 7mg & 14mg Tablets.

              Lead Product(s): Teriflunomide

              Therapeutic Area: Immunology Product Name: Teriflunomide-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Breckenridge Pharmaceutical

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2021

              Axplora CB

              Iran Expo

              Not Confirmed

              envelop Contact Supplier

              Axplora

              Contact Supplier
              • Deals
              Virtual BoothAxplora- The partner of choice for complex APIs.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement

              Details:

              Novasep will be in charge of developing and manufacturing the two AAV vectors designed for the Sensorion OTOF-GT project and will supply Drug Product batches to support preclinical and clinical studies.

              Lead Product(s): OTOF-GT,Aav Vectors

              Therapeutic Area: Genetic Disease Product Name: OTOF-GT

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Sensorion

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 27, 2020

              Axplora CB

              Iran Expo

              Not Confirmed

              envelop Contact Supplier

              Axplora

              Contact Supplier
              • Deals
              Virtual BoothAxplora- The partner of choice for complex APIs.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novasep and Lysogene Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product

              Details:

              With this collaboration, the two companies consolidate their long-lasting partnership initiated with the development and manufacturing of Lysogene's lead gene therapy product, LYS-SAF302, currently in clinical phase 2/3.

              Lead Product(s): LYS-GM101

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Lysogene

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 26, 2020

              Axplora CB

              Iran Expo

              Not Confirmed

              envelop Contact Supplier
              Axplora VB RM
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY